Studies on influenza virus transmission between ferrets: The public health risks revisited

mBio

Volumn 6, Issue 1, 2015, Pages

  Fouchier, Ron A M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OSELTAMIVIR;

AEROSOL; AIRBORNE INFECTION; AVIAN INFLUENZA VIRUS; BIOSAFETY; EPIDEMIC; FERRET; HEALTH HAZARD; INFECTION CONTROL; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; LABORATORY ACQUIRED INFECTION; LABORATORY INFECTION; LETTER; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; RISK ASSESSMENT; RISK REDUCTION; SEASONAL INFLUENZA; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS VIRULENCE; INFLUENZA A VIRUS; MEDICAL RESEARCH; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PATHOGENICITY; PROCEDURES; SARS CORONAVIRUS; TRENDS; VIROLOGY; VIRUS INFECTION;

MUSTELA; ORTHOMYXOVIRIDAE;

BIOMEDICAL RESEARCH; INFLUENZA A VIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; SARS VIRUS; VIRUS DISEASES;

EID: 84924185974     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02560-14     Document Type: Letter

References (33)

1. Lipsitch M, Inglesby TV. 2014. Moratorium on research intended to create novel potential pandemic pathogens. mBio 5: e02366-14. http://dx. doi. org/10. 1128/mBio. 02366-14.
2. Lipsitch M, Galvani AP. 2014. Ethical alternatives to experiments with novel potential pandemic pathogens. PLoS Med 11: e1001646. http://dx. doi. org/10. 1371/journal. pmed. 1001646.
3. Merler S, Ajelli M, Fumanelli L, Vespignani A. 2013. Containing the accidental laboratory escape of potential pandemic influenza viruses. BMC Med 11: 252. http://dx. doi. org/10. 1186/1741-7015-11-252.
4. Klotz LC, Sylvester EJ. 2014. The consequences of a lab escape of a potential pandemic pathogen. Front Public Health 2: 116. http://dx. doi. org/10. 3389/fpubh. 2014. 00116.
5. Schultz-Cherry S, Webby RJ, Webster RG, Kelso A, Barr IG, McCauley JW, Daniels RS, Wang D, Shu Y, Nobusawa E, Itamura S, Tashiro M, Harada Y, Watanabe S, Odagiri T, Ye Z, Grohmann G, Harvey R, Engelhardt O, Smith D, Hamilton K, Claes F, Dauphin G. 2014. Influenza gain-of-function experiments: their role in vaccine virus recommendation and pandemic preparedness. mBio 5: e02430-14. http://dx. doi. org/10. 1128/mBio. 02430-14.
6. Davis CT, Chen LM, Pappas C, Stevens J, Tumpey TM, Gubareva LV, Katz JM, Villanueva JM, Donis RO, Cox NJ. 2014. Use of highly pathogenic avian influenza A(H5N1) gain-of-function studies for molecularbased surveillance and pandemic preparedness. mBio 5: e02431-14. http://dx. doi. org/10. 1128/mBio. 02431-14.
7. Henkel RD, Miller T, Weyant RS. 2012. Monitoring select agent theft, loss and release reports in the United States-2004-2010. Appl Biosaf 18: 171-180. http://www. absa. org/abj/abj/121704FAHenkel. pdf.
8. U. S. Department of Homeland Security. 2008. National bio and agrodefense facility: final environmental impact statement, appendix B. US Department of Homeland Security, Washington, DC. http://www. dhs. gov/xlibrary/assets/nbaf_feis_appendix_b. pdf.
9. Kimman TG, Smit E, Klein MR. 2008. Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures. Clin Microbiol Rev 21: 403-425. http://dx. doi. org/10. 1128/CMR. 00014-08.
10. WHO. 2006. Biorisk management laboratory biosecurity guidance. http://www. who. int/csr/resources/publications/biosafety/WHO_CDS_EPR_2 006_6. pdf?ua_1.
11. Jonsson CB, Cole KS, Roy CJ, Perlin DS, Byrne G, members of the RBL-NBL Directors Network. 2013. Challenges and practices in building and implementing biosafety and biosecurity programs to enable basic and translational research with select agents. J Bioterror Biodef 2013(Suppl 3): 12634. http://dx. doi. org/10. 4172/2157-2526. S3-015.
12. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541. http://dx. doi. org/10. 1126/science. 1213362.
13. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428. http://dx. doi. org/10. 1038/nature10831.
14. Sutton TC, Finch C, Shao H, Angel M, Chen H, Capua I, Cattoli G, Monne I, Perez DR. 2014. Airborne transmission of highly pathogenic H7N1 influenza virus in ferrets. J Virol 88: 6623-6635. http://dx. doi. org/10. 1128/JVI. 02765-13.
15. Zhang Y, Zhang Q, Kong H, Jiang Y, Gao Y, Deng G, Shi J, Tian G, Liu L, Liu J, Guan Y, Bu Z, Chen H. 2013. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340: 1459-1463. http://dx. doi. org/10. 1126/science. 1229455.
16. Linster M, van Boheemen S, de Graaf M, Schrauwen EJ, Lexmond P, Mänz B, Bestebroer TM, Baumann J, van Riel D, Rimmelzwaan GF, Osterhaus AD, Matrosovich M, Fouchier RA, Herfst S. 2014. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. Cell 157: 329-339. http://dx. doi. org/10. 1016/j. cell. 2014. 02. 040.
17. United States Government. 2014. U. S. government gain-of-function deliberative process and research funding pause on selected gain-offunction research involving influenza, MERS, and SARS viruses. http://www. phe. gov/s3/dualuse/Documents/gain-of-function. pdf.
18. Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. 2012. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 metaanalyses. Hum Vaccin Immunother 8: 851-862. http://dx. doi. org/10. 4161/hv. 19917.
19. Couch RB. 2008. Seasonal inactivated influenza virus vaccines. Vaccine 26(Suppl 4): D5-D9. http://dx. doi. org/10. 1016/j. vaccine. 2008. 05. 076.
20. Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. 2014. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One 9: e113633. http://dx. doi. org/10. 1371/journal. pone. 0113633.
21. Te Beest DE, van Boven M, Bos ME, Stegeman A, Koopmans MP. 2010. Effectiveness of personal protective equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 2003. Emerg Infect Dis 16: 1562-1568. http://dx. doi. org/10. 3201/eid1610. 091412.
22. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246. http://dx. doi. org/10. 1001/jama. 282. 13. 1240.
23. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194: 159-167. http://dx. doi. org/10. 1086/505225.
24. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424. http://dx. doi. org/10. 1128/AAC. 01312-06.
25. Eames KT, Tilston NL, Brooks-Pollock E, Edmunds WJ. 2012. Measured dynamic social contact patterns explain the spread of H1N1v influenza. PLoS Comput Biol 8: e1002425. http://dx. doi. org/10. 1371/journal. pcbi. 1002425.
26. Richard M, Schrauwen EJ, de Graaf M, Bestebroer TM, Spronken MI, van Boheemen S, de Meulder D, Lexmond P, Linster M, Herfst S, Smith DJ, van den Brand JM, Burke DF, Kuiken T, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2013. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 501: 560-563. http://dx. doi. org/10. 1038/nature12476.
27. Palese P, Wang TT. 2012. H5N1 influenza viruses: facts, not fear. Proc Natl Acad Sci U S A. 109: 2211-2213. http://dx. doi. org/10. 1073/pnas. 1121297109.
28. Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A. 2014. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6: 2735-2761. http://dx. doi. org/10. 3390/v6072735.
29. Stokes J, Jr., Weibel RE, Villarejos VM, Arguedas JA, Buynak EB, Hilleman MR. 1971. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA 218: 57-61. http://dx. doi. org/10. 1001/jama. 218. 1. 57.
30. Beare AS, Schild GC, Craig JW. 1975. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet ii: 729-732. http://dx. doi. org/10. 1016/S0140-6736(75)90720-5.
31. WHO. 2014. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. http://www. who. int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/.
32. Van Kerkhove MD, Riley S, Lipsitch M, Guan Y, Monto AS, Webster RG, Zambon M, Nicoll A, Peiris JS, Ferguson NM. 2012. Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". Science 336:; author reply: 1506. http://dx. doi. org/10. 1126/science. 1221434.
33. Wang TT, Parides MK, Palese P. 2012. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 335: 1463. http://dx. doi. org/10. 1126/science. 1218888.